Solid Biosciences Clinical Hold on IGNITE DMD is Lifted by the FDA
Solid Biosciences (SLDB) - a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that the U.S. FDA has lifted the clinical hold placed on the Company’s IGNITE DMD Phase 1/2 clinical trial.
The FDA had requested further manufacturing information, updated safety and efficacy . . .
This content is for paid subscribers.
Today’s Highlights October 1, 2020